Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cholecystokinin and the hormone concept

    Research output: Contribution to journalReviewpeer-review

  2. Free testosterone and cardiometabolic parameters in men: comparison of algorithms

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prenatal paraben exposure and anogenital distance and reproductive hormones during mini-puberty: A study from the Odense Child Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The calcium-sensing receptor is essential for calcium and bicarbonate sensitivity in human spermatozoa

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Establishment of a novel human fetal adrenal culture model that supports de novo and manipulated steroidogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Possible Relevance of Soluble Luteinizing Hormone Receptor during Development and Adulthood in Boys and Men

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. CPMS-improving patient care in Europe via virtual case discussions

    Research output: Contribution to journalReviewpeer-review

  • Gudmundur Johannsson
  • Martin Bidlingmaier
  • Beverly Biller
  • Margaret Boguszewski
  • Felipe F Casanueva
  • Philippe Chanson
  • Catherine S Choong
  • Peter E Clayton
  • David Clemmons
  • Mehul Dattani
  • Jan Frystyk
  • Ken K Y Ho
  • Andrew Hoffman
  • Reiko Horikawa
  • Anders Juul
  • John Kopchick
  • Xiaoping Luo
  • Sebastian Neggers
  • Irène Netchine
  • Daniel S Olsson
  • Sally Radovick
  • Ron G Rosenfeld
  • Richard J Ross
  • Katharina Schilbach
  • Paulo Ferrez Collett-Solberg
  • Christian J Strasburger
  • Peter J Trainer
  • Kerstin Wickstrom
  • Kevin Cj Yuen
  • Jens Otto Lunde Jørgensen
View graph of relations

OBJECTIVE: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults, and in patients with acromegaly.

PARTICIPANTS: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry.

EVIDENCE: Current literature was reviewed and expert opinion was utilized to establish the state of the art, and identify current gaps and unmet needs.

CONSENSUS PROCESS: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process.

CONCLUSIONS: The clinical endpoint in pediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of co-morbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.

Original languageEnglish
JournalEndocrine Connections
Volume7
Issue number3
Pages (from-to)R126-R134
ISSN2049-3614
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 53311933